10-Q/A: iAnthus Capital Holdings Restates Q3 2023 Financials Due to Inventory and Consolidation Errors

iAnthus Capital Holdings has filed an amended quarterly report to correct errors related to inventory valuation and intercompany consolidation, impacting previously reported financials for Q3 2023.

Summary

• iAnthus Capital Holdings has restated its Q3 2023 financial statements due to errors in inventory valuation and intercompany consolidation.
• The errors led to an overstatement of 'inventories, net' and 'accrued and other current liabilities' on the balance sheet as of September 30, 2023.
• There was also an overstatement of 'income tax expense' and an understatement of 'cost and expenses applicable to revenues' on the income statement for the three and nine months ended September 30, 2023.
• The restatement did not affect the cash balance as of September 30, 2023, or net cash flows for the nine months ended September 30, 2023.
• The company's Q3 2023 revenue was $42.9 million, with a gross profit of $13.3 million.
• The net loss for Q3 2023 was $19.2 million, or $0.00 per share.
• For the nine months ended September 30, 2023, the company's revenue was $118.4 million, with a gross profit of $47.3 million.
• The net loss for the nine months ended September 30, 2023, was $57.9 million, or $0.01 per share.

Sentiment

Score: 4

Explanation: The document reveals significant financial challenges, including a restatement due to material weaknesses in internal controls, substantial net losses, and a working capital deficit. While there are some positive aspects, such as revenue growth in the Eastern region, the overall tone is negative due to the financial and operational issues.

Positives

• The company's cash balance was not impacted by the restatement.
• The company's net cash flows were not impacted by the restatement.
• The company's revenue increased in the Eastern region by 26.4% in Q3 2023 compared to Q3 2022.
• The company's gross profit margin increased in the Western region in Q3 2023 compared to Q3 2022.

Negatives

• The company's Q3 2023 gross profit margin decreased in the Eastern region compared to Q3 2022.
• The company's Q3 2023 revenue decreased in the Western region by 16.2% compared to Q3 2022.
• The company's Q3 2023 net loss was $19.2 million.
• The company's net loss for the nine months ended September 30, 2023, was $57.9 million.
• The company has a working capital deficit of $82.7 million as of September 30, 2023.
• The company has an accumulated deficit of $1,308.9 million as of September 30, 2023.

Risks

• The company's internal controls over financial reporting were not effective as of September 30, 2023, due to material weaknesses.
• The company's ability to continue as a going concern is dependent on raising additional capital and achieving sustainable revenues.
• The company is subject to the limitations of Internal Revenue Code Section 280E.
• The company is involved in several legal proceedings, which could have a material adverse effect on its financial position.
• The company's outstanding debt instruments impose certain restrictions on its operating and financing activities.

Future Outlook

The company expects total operating expenses to remain consistent over the remainder of 2023 and expects to continue to have positive cash flows from operations, but no assurance can be given that it will have positive cash flows in the future.

Management Comments

• Management has concluded that the company's internal controls over financial reporting were, and continue to be, ineffective.
• Management is working to remediate the material weakness related to inventory valuation.

Industry Context

The company operates in the cannabis industry, which is subject to federal illegality and evolving state regulations. The company's performance is affected by competition, price compression, and regulatory changes.

Comparison to Industry Standards

• The company's gross profit margins in the Eastern region decreased due to price compression, which is a common challenge in the cannabis industry.
• The company's revenue decrease in the Western region is indicative of the competitive landscape in those markets.
• The company's operating expenses are being managed to control discretionary spending, which is a common practice in the industry.
• The company's net losses are not uncommon in the cannabis industry, especially for companies undergoing restructuring and expansion.

Management Changes

Legal Proceedings

• The company is involved in several legal proceedings, including the Hi-Med matter, the Walmer matter, and a claim by a former financial advisor.
• The company has reached a settlement in principle with Hi-Med and is in the process of finalizing a settlement agreement.
• The company is in the process of reviewing Canaccord's Motion for Summary Judgment and will file an opposition in due course.

Related Party Transactions

• Certain of the company's lenders held greater than 5% of the voting interests in the company upon the closing of the Recapitalization Transaction and are classified as related parties.
• The company has a related party payable of $7.7 million due to certain of the New Secured Lenders for Deferred Professional Fees.
• The company made payments to former executives Randy Maslow and Julius Kalcevich as part of separation agreements.

Stakeholder Impact

• Shareholders are impacted by the restatement of financials and the material weaknesses in internal controls.
• Employees are impacted by the company's cost-cutting measures and changes in management.
• Customers are impacted by the company's operational changes and product offerings.
• Creditors are impacted by the company's debt obligations and financial performance.

Next Steps

• The company will continue to implement improved processes and internal controls to ensure the proper application of accounting practices and guidance.
• The company will seek to dedicate additional accounting resources to assessing its existing internal controls.
• The company will provide additional review of high-risk areas from senior personnel in its inventory valuation models.
• The company will continue to monitor its cash on-hand and its expenditures required to execute its day-to-day operations and its long-term strategic plans.

Key Dates

Keywords

cannabis, financial restatement, inventory, consolidation, multi-state operator, financial results, debt, legal proceedings, internal controls, going concern